European Pharma

Novo Nordisk has offloaded its Parkinson's cell therapy operations to AI-enabled partner Cellular Intelligence, signaling a broader European pharma pivot away from vertical integration. The Danish drugmaker posted a Q1 2026 earnings beat alongside a 24.9% 30-day stock surge. The move reflects a structural shift as NVIDIA's BioNeMo platform increasingly connects Big Pharma with AI-native drug discovery networks.

Novo Nordisk surged 24.9% in 30 days after exiting internal cell therapy and licensing AI-enabled development to Cellular Intelligence, which holds FDA Fast Track status for a Parkinson's program. NVIDIA's BioNeMo platform is simultaneously embedding into biopharma R&D through Thermo Fisher and Eli Lilly partnerships. European biotechs now face a structural choice: build proprietary AI infrastructure or depend on US-based platform providers.

Novo Nordisk posted a 24.9% stock gain over 30 days following strong Q1 2026 earnings, as the Danish pharma giant bets on AI-augmented pipelines and exits its internal cell therapy unit. Meanwhile, French AI biotech Owkin competes with its OwkinZero platform as NVIDIA's BioNeMo infrastructure becomes a shared backbone across the sector.

Novo Nordisk licensed its Parkinson's cell therapy program to Cellular Intelligence and shut its internal cell therapy unit. The company's shares gained 24.9% over 30 days as investors backed its GLP-1 refocus. The move reflects a broader pharma trend of outsourcing early-stage biology to AI-native partners while concentrating resources on validated commercial assets.

Novo Nordisk's decision to shutter its internal cell therapy unit and hand its Parkinson's program to AI-enabled Cellular Intelligence triggered a 24.9% stock surge, signalling market approval for asset-light, AI-accelerated models. NVIDIA's BioNeMo platform is emerging as the connective infrastructure linking European pharma incumbents to a new generation of AI-native drug discovery companies. A concurrent wave of specialised biological foundation models indicates the platform layer is maturing

Swiss specialty pharmaceutical company Santhera Pharmaceuticals faces significant pipeline concentration risk, with its entire commercial future effectively staked on a single asset — vamorolone — for Duchenne Muscular Dystrophy. As the company has already licensed out its Japan and Asia-Pacific rights to Nxera, any setback to vamorolone's European trajectory could leave thousands of DMD patients without a key treatment alternative and Santhera with little commercial fallback.